BioLineRx Entered Exclusive License Agreement for the Development of Motixafortide in Asia, Advised by MSQ Ventures
NEW YORK, Oct. 31, 2023 /PRNewswire/ — MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has
Read More